<!DOCTYPE html>
<html>
    <head>
        <title>STD Tx Guidelines</title>
    </head>
    <body>
        <!-- Start of page -->
        <div data-role="page" id="g19" data-theme="a">
            <div data-role="header" data-id="guidelines-header" data-theme="b" data-position="fixed">
                <a href="lv-6.html" class="ui-btn ui-icon-back ui-btn-icon-notext ui-corner-all" aria-label="back"></a>
                <h3>STD Tx Guidelines</h3>
	<a href="../menu.html" class="ui-btn ui-icon-grid ui-btn-icon-notext ui-corner-all" aria-label="main menu"></a>
            </div>
            <div data-role="content">
            <div id=guidelines_breadcrumbs>
            
                    <a href="lv-4.html" >Full Guidelines</a><span class="carrot"> > </span>
                    <a href="lv-4.html" >Clinical Prevention Guidance</a><span class="carrot"> > </span>
                    <a href="lv-6.html" >Prevention Methods</a><span class="carrot"> > </span>Pre-exposure Prophylaxis (PrEP) for HIV and STD
            </div>
            </br><h3 class="sgc-1" id="sigil_toc_id_19">
 Pre-exposure Prophylaxis (PrEP) for HIV and STD
</h3>
<p>
 Antiretroviral therapy (ART) has the potential to impact transmission and acquisition of HIV. In HIV-infected persons, ART reduces viral load and presumably reduces infectiousness (60). In HIV-uninfected persons, ART might reduce susceptibility to infection, a concept supported both by animal studies and by a study of safety and acceptability involving West African women (61,62). A randomized, placebo-controlled&nbsp;trial involving South African women recently demonstrated that use of tenofovir gel associated with sexual intercourse significantly reduced the rate of HIV and herpes simplex virus type 2 (HSV-2) acquisition by 39% and 51%, respectively (47,63).
</p>
<p>
 Several large randomized controlled trials of PrEP are either underway or planned. These involve the oral use of non-nucleoside reverse transcriptase inhibitors (tenofovir or tenofovir-emtricitabine) or vaginal use of 1% tenofovir gel.
</p>

            </div>
        </div>
        <!-- end of guidelines heading page -->
    </body>
</html>

